[{"id":"d16edb9e-05b0-4a67-8757-e2748c115c02","acronym":"ARST1431","url":"https://clinicaltrials.gov/study/NCT02567435","created_at":"2024-01-09T20:20:40.495Z","updated_at":"2025-02-25T16:51:34.054Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","source_id_and_acronym":"NCT02567435 - ARST1431","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FOXO1 • PAX3 • PAX7","pipe":"","alterations":" ","tags":["FOXO1 • PAX3 • PAX7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • irinotecan • temsirolimus • vincristine • vinorelbine tartrate • dactinomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"6365efdc-854e-4454-ba10-f28f09a5a11b","acronym":"PEPN2112","url":"https://clinicaltrials.gov/study/NCT05071209","created_at":"2021-10-08T11:53:44.641Z","updated_at":"2025-02-25T17:01:24.348Z","phase":"Phase 1/2","brief_title":"Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT05071209 - PEPN2112","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3","pipe":" | ","alterations":" PAX3-FOXO1 fusion","tags":["BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PAX3-FOXO1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e elimusertib (BAY 1895344)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/22/2021","start_date":" 12/22/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 11/22/2025","study_completion_date":" 11/22/2025","last_update_posted":"2025-02-03"},{"id":"098eedc3-67f7-4011-92ca-34ff95af6008","acronym":"","url":"https://clinicaltrials.gov/study/NCT01609803","created_at":"2021-11-07T20:52:59.586Z","updated_at":"2024-07-02T16:37:32.049Z","phase":"","brief_title":"Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma","source_id_and_acronym":"NCT01609803","lead_sponsor":"Children's Oncology Group","biomarkers":" PAX3 • PAX7","pipe":"","alterations":" ","tags":["PAX3 • PAX7"],"overall_status":"Completed","enrollment":" Enrollment 99","initiation":"Initiation: 06/01/2012","start_date":" 06/01/2012","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2016-05-18"},{"id":"2fe4c63b-c739-4dec-abba-b5b3787d33a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01668095","created_at":"2021-01-18T07:12:51.077Z","updated_at":"2024-07-02T16:37:32.079Z","phase":"","brief_title":"Biomarkers in Patients With Advanced Rhabdomyosarcoma","source_id_and_acronym":"NCT01668095","lead_sponsor":"Children's Oncology Group","biomarkers":" PTCH1 • PAX3 • PAX7","pipe":"","alterations":" ","tags":["PTCH1 • PAX3 • PAX7"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/01/2012","start_date":" 08/01/2012","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":"","study_completion_date":"","last_update_posted":"2016-05-18"}]